Koppel Jeremy, Sunday Suzanne, Goldberg Terry E, Davies Peter, Christen Erica, Greenwald Blaine S
Litwin Zucker Alzheimer's Research Center, Manhasset, NY.
Litwin Zucker Alzheimer's Research Center, Manhasset, NY.
Am J Geriatr Psychiatry. 2014 Jul;22(7):698-707. doi: 10.1016/j.jagp.2012.10.028. Epub 2013 Mar 15.
An ascendant body of evidence suggests that Alzheimer disease with psychosis (AD+P) is a distinct variant of illness with its own genetic diathesis and a unique clinical course. Impaired frontal lobe function has been previously implicated in AD+P. The current exploratory study, presented in two parts, evaluates both the regional brain metabolic and psychometric correlates of psychosis in a longitudinal sample of subjects with AD, made available by the Alzheimer's Disease Neuroimaging Initiative (ADNI).
In Part 1 of the study, 21 ADNI participants with AD who developed psychotic symptoms during the study but were not psychotic at baseline were matched with 21 participants with AD who never became psychotic during the study period, and mean brain [F(18)]fluorodeoxyglucose positron emission tomography (FDG-PET) Cerebral metabolic rate for glucose (CMRgl) by regions of interest (ROIs) were compared Additionally, 39 participants with active psychosis at the time of image acquisition were matched with 39 participants who were never psychotic during the study period, and mean brain FDG-PET CMRgl by sROI were compared. In Part 2 of the study, 354 ADNI participants with AD who were followed for 24 months with serial psychometric testing were identified, and cognitive performance and decline were evaluated for correlation with psychotic symptoms.
Part 1: There were no regional brain metabolic differences between those with AD destined to become psychotic and those who did not become psychotic. There was a significant reduction in mean orbitofrontal brain metabolism in those with active psychosis. Part 2: Over the course of study follow-up, psychosis was associated with accelerated decline in functional performance as measured by the Functional Assessment Questionnaire, the Mini-Mental State Examination, and Forward Digit Span.
In a sample drawn from the ADNI dataset, our exploratory FDG-PET findings and longitudinal cognitive outcomes support the hypofrontality model of AD+P. Focal frontal vulnerability may mediate the accelerated decline seen in AD+P.
越来越多的证据表明,伴有精神病性症状的阿尔茨海默病(AD+P)是一种具有独特遗传素质和临床病程的疾病变体。此前已有研究表明额叶功能受损与AD+P有关。本探索性研究分为两部分,通过阿尔茨海默病神经影像学计划(ADNI)提供的纵向样本,评估AD患者精神病性症状的脑区代谢和心理测量学相关性。
在研究的第一部分,将21名在研究期间出现精神病性症状但基线时无精神病性症状的ADNI AD患者与21名在研究期间从未出现精神病性症状的AD患者进行匹配,并比较感兴趣区域(ROI)的平均脑[F(18)]氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)葡萄糖脑代谢率(CMRgl)。此外,将39名在图像采集时患有活动性精神病性症状的参与者与39名在研究期间从未患有精神病性症状的参与者进行匹配,并比较感兴趣子区域(sROI)的平均脑FDG-PET CMRgl。在研究的第二部分,确定了354名接受了24个月系列心理测量测试的ADNI AD患者,并评估了认知表现和衰退与精神病性症状的相关性。
第一部分:注定会出现精神病性症状的AD患者与未出现精神病性症状的AD患者之间在脑区代谢方面无差异。患有活动性精神病性症状的患者眶额平均脑代谢显著降低。第二部分:在研究随访过程中,根据功能评估问卷、简易精神状态检查和顺背数字广度测量,精神病性症状与功能表现的加速衰退相关。
在从ADNI数据集中抽取的样本中,我们的探索性FDG-PET研究结果和纵向认知结果支持AD+P的额叶功能减退模型。额叶局灶性易损性可能介导了AD+P中出现的加速衰退。